INTRODUCTION
Brain tumors are a group of tumors that have a high level of morbidity and mortality worldwide (Bouffet et al., 2010) . Gliomas are the most common primary common central nervous system tumors in adults, accounting for nearly 80% of all primary malignant brain tumors (Schwartzbaum et al., 2006) . Although numerous studies have examined the etiology of glioma, there have been no conclusive results.
Previous studies indicated that damaged DNA or lower DNA repair capacity contributes to genetic instability and the occurrence and development progress of malignant tumors (Audebert et al., 2004; Matullo et al., 2006; Abdel-Rahman and El-Zein, 2011) . DNA repair genes, which play an important role in repairing damaged DNA, may prevent the activation of oncogenes or inactivation of tumor-suppressor genes (Abdel-Rahman and El-Zein, 2011) . Over the past decade, an increasing number of polymorphisms in DNA repair genes have been identified and their involvement in several types of tumors was studied (Audebert et al., 2004; Matullo et al., 2006; Liu et al., 2007; Tahara et al., 2011) .
Among the genes identified, the X-ray cross complementing group 3 (XRCC3) gene may influence the capacity to repair DNA damage, leading to increased cancer susceptibility. The functional single-nucleotide polymorphism (SNP) of XRCC3, Thr241Met (rs861539), is located at codon 241 in exon 7 with a C to T transition (Liu et al., 1998) . Several studies have found this variant is a susceptibility factor for several cancers, including lung, breast, colorectal, and bladder cancers (Liu et al., 2007; Yan et al., 2009; Abdel-Rahman and El-Zein, 2011; Romanowicz-Makowska et al., 2012; Zhao et al., 2012) . Moreover, some studies found that the XRCC3 Thr241Met polymorphism is associated with glioma risk (Wang et al., 2004; Yosunkaya et al., 2010) . However, the cumulative results remain inconclusive because of the different ethnicities, research samples, ages, and subtypes of glioma included in the studies.
In this study, we sequenced the XRCC3 gene Thr241Met polymorphism to investigate the relationship between the XRCC3 Thr241Met polymorphism and glioma risk.
MATERIAL AND METHODS

Study subjects
The glioma patients and healthy controls recruited in this study were enrolled from Xiangya Hospital of Central South University during 2007-2013. All cases recruited in this study were histologically confirmed. Controls were randomly selected from people who requested general health examinations in the same hospital. Healthy controls were required to have no history of any type of cancer.
The clinical study admission (registration number: ChiCTR-RO-12002853) was approved by Chinese Clinical Trail Register. The study protocol was approved by the Ethics Committee of Xiangya School of Medicine and Ethics Committee of Institute of Clinical Pharmacology of Central South University. All patients and healthy controls were investigated by face-to-face interviewing with a questionnaire by doctors or nurses. All patients signed consent forms before participating in the study.
Genotyping
DNA was isolated from 3 mL whole blood samples using the phenol-chloroform extraction method and then stored at 4°C until use. The primer pairs used for amplification of the XRCC3 Thr241Met (rs861539) locus were as follows: sense primer: 5'-GGTCGAGTGACA GTCCAAAC-3', antisense primer: 5'-CTACCCGCAGGAGCCGGAGG-3'. Polymerase chain reaction (PCR) amplifications were carried out in a total volume of 25 µL containing 2.5 µL 10X PCR buffer (containing MgCl2) (Takara, Shiga, Japan), 0.2 mM of each dNTP (Takara), 0.4 mM of each primer, 200 ng genomic DNA as a template, and 1 U Taq polymerase (Takara). The PCR conditions were as follows: predenaturation at 94°C for 5 min; 30 cycles each of denaturing at 94°C for 30 s, annealing 58°C for 30 s, and extension at 72°C for 30 s; and extension at 72°C for 8 min. The PCR products were directly sequenced. PCR fragments were purified with PCR Clean-Up System (Promega, Southampton, UK), sequenced using the BigDye Terminator v. 1.1 Cycle Sequencing Kit [Applied Biosystems (ABI), Weiterstadt, Germany], and the sequencing products were sequenced by ABI 3130 Genetic Analyzer.
Statistical analysis
The SPSS software package version 13.0 (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. Hardy-Weinberg equilibrium was tested with χ 2 test or Fisher's exact test as applicable in the case-control samples. Data pertaining to age and gender as well as other characteristics were compared between glioma patients and healthy controls using the Student t-test or chi-square analysis. The relationship between various genotypes or alleles and the susceptibility to glioma was examined using the χ 2 test. Statistical significance was accepted when P < 0.05. 
RESULTS
A total of 389 patients (199 males, 190 female, age: 48.6 ± 9.8 years) and 358 healthy controls (174 males, 184 female, age: 47.6 ± 10.4 years) were enrolled in our study. The demographic and clinical characteristics of patients are shown in Table 1 . There were no differences between the 2 groups regarding gender and age distribution. The 389 glioma cases consisted of 185 (47.6%) glioblastoma, 95 (24.4%) anaplastic astrocytoma or diffuse astrocytoma or other astrocytoma, and 109 (28%) other gliomas. We sequenced the XRCC3 gene Thr241Met (rs861539) polymorphism in 389 glioma patients and 358 healthy controls and identified 2 additional polymorphisms, rs3212112 (c.774+19T>G) and rs1799796 (c.562-14A>G). The position of the SNPs and their relationship with the exon-intron boundaries of XRCC3 are shown in Table 2 .
The SNPs investigated were all in Hardy-Weinberg equilibrium. The allele and genotype frequencies of the 3 SNPs in glioma patients (N = 389) and healthy controls (N = 358) are shown in Table 3 . We found that the XRCC3 gene rs1799796 and rs861539 alleles and genotypes were associated with glioma in our Chinese population. The frequency of the rs861539 T allele was significantly lower in the glioma group than in healthy controls [11.1 vs 17.7%, odds ratio (95% confidence interval) = 0.62 (0.48-0.80), P < 0.001]; the frequencies of the CT or CT+TT genotypes differed between groups (18.5 vs 31%, 20.3 vs 33.2%, respectively). The frequency of the rs3212112 G allele was significantly higher in the glioma group than in healthy controls [15.8 vs 5.3%, odds ratio (95% confidence interval) = 2.94 (2.07-4.17), P < 0.001]; the frequencies of the GT or TG+GG genotypes differed between the 2 groups (25.4 vs 7.8%, 28.5 vs 9.2%, respectively). We observed no difference in allele or genotypes frequencies for rs1799796 between the glioma patients and healthy controls after Bonferroni correction. 
DISCUSSION
Numerous studies have demonstrated that DNA injury and repair play an important role in the occurrence and development of various types of tumors. Moreover, there is evidence that some SNPs in the DNA repair pathway genes can modify the DNA repair capability and increase cancer risk (Takanami et al., 2005) . XRCC3 belongs to the DNA double-strand break repair pathway. Previous studies found that the XRCC3 Thr241Met (rs861539) polymorphism may influence DNA repair capacity and also showed that the XRCC3 Thr241Met polymorphism may be associated with cancer risk (Matullo et al., 2006; Liu et al., 2007; López-Cima et al., 2007; Romanowicz-Makowska et al., 2012) . Numerous studies have examined the relationship between the XRCC3 Thr241Met polymorphism and glioma risk, and meta-analysis studies showed positive results (Liang et al., 2013; Zhao et al., 2013; Wang et al., 2014) and also some negative results (Kiuru et al., 2008; Feng et al., 2014) . The association strength between XRCC3 Thr241Met and glioma susceptibility remains unclear and requires further analysis.
In this case-control study, we analyzed 3 SNPs in XRCC3 in 389 glioma patients and 358 controls. We found that rs861539 and rs3212112 were significantly associated with glioma risk. These findings suggest that XRCC3 SNPs can be used as markers for testing the genetic susceptibility to glioma. Our results were consistent with those of several studies reporting that rs861539 Thr241Met is a risk allele for glioma. The DNA repair protein XRCC3 contains 346 amino acids and is involved in the repair of DNA strand breaks via the homologous recombination repair pathway (Lee et al., 2007) . The XRCC3 Thr241Met polymorphism (rs861539), located in exon 7, shows substitution of thymine (T) to cytosine (C) at codon 241, changing threonine (Thr) to methionine (Met), which may affect enzyme function and/or its interaction with other proteins involved in DNA damage repair (Matullo et al., 2001; Jiao et al., 2008; Williams and Sobol, 2013) . Previous meta-analysis studies have examined the XRCC3 Thr241Met polymorphism and glioma risk. Most of the results were consistent with our results showing that the XRCC3 Thr241Met polymorphism is a risk factor for glioma. However, Feng et al. (2014) , who analyzed 8 case-control studies including a total of 3455 glioma cases and 4435 controls, found no significant association between the XRCC3 T241M polymorphism and glioma (Feng et al., 2014) . In subgroup analysis, this polymorphism appeared to be associated with an increased glioma risk in Asians in their analysis (Feng et al., 2014) . Only 4 case-control studies have examined Asian glioma patients (Zhou et al., 2009; Liu et al., 2012; Luo et al., 2013; Pan et al., 2013) , and more sample sizes are needed to confirm whether an association exists between the XRCC3 T241M polymorphism and glioma risk.
In this study, we found that the XRCC3 rs3212112 polymorphism was significantly associated with glioma risk. The frequency of the XRCC3 rs3212112 G allele was 15.8% in glioma patients and 5.3% in healthy controls. The frequencies of the TG or GG and TG+GG genotypes were significantly higher in glioma patients. The XRCC3 rs3212112 polymorphism is located in an intron of the XRCC3 gene, and the function of this polymorphism is unknown. In our study, we found that the heterozygotes TG and TG+GG variants of XRCC3 increased the risk of glioma by 3.3-and 3.1-fold, respectively, compared to the homozygous wild-type genotype.
In conclusion, our case-control analysis of 3 SNPs in the XRCC3 gene suggests that rs861539 and rs3212112 in the XRCC3 gene are associated with glioma risk. Our study provides important information regarding the etiology of glioma. Furthermore, large-sample studies are needed to validate our results.
